Improving Diagnosis and Treatment of Anxiety in Parkinson’s Disease: IDATA-PD Study
Objective: We investigated PD-specific features of anxiety for clear conceptualisation, and assessed targeted psychotherapy for anxiety in Parkinson’s disease (PD). Background: Anxiety is poorly diagnosed in PD…Tongue strength in Parkinson’s disease.
Objective: To investigate tongue strength in patients with Parkinson’s disease and the relation with speech and swallowing. Background: Motor disorders in Parkinson’s disease (PD) are…High intensity interval training improves psychomotor function in individuals with Parkinson’s disease
Objective: The study aimed to examine the effects of high intensity interval training (HIIT) on neurological, psychological and biomechanical aspects of psychomotor behaviors in Parkinson’s…Developing a guide to facilitate involving people with Parkinson’s and their carers in service improvement
Objective: To develop an easy-to-use guide for service development project leads and patients/carers to facilitate the involvement of the latter in the development and implementation…Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Preliminary Results from a Phase III Study
Objective: To determine the safety of single treatments of APL-130277 in patients with Parkinson’s disease (PD). Background: Patients with Parkinson’s disease (PD) frequently develop problematic…Four year outcomes of a prospective, multi-center trial evaluating Deep Brain Stimulation with a new multiple-source, constant-current rechargeable system in Parkinson’s disease
Objective: To evaluate the four year, long-term follow up results of patients in the VANTAGE clinical study that employed multiple independent current control (MICC) Deep Brain…Five year longitudinal change in the MDS-UPDRS scores in early Parkinson’s disease participants: Results from the PPMI Study
Objective: To determine the longitudinal change in the Movement Disorder Society –Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) in Parkinson’s disease (PD) participants who were untreated…A Phase 3 Study of isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): Baseline characteristics and study update
Objective: To evaluate the efficacy of isradipine 10 mg daily to slow progression of disability in early PD. Background: Isradipine, a dihydropyridine calcium channel antagonist,…Altered attentional brain network in Parkinson’s disease with mild cognitive impairment
Objective: To investigate alterations in the attention network in Parkinson’s disease patients with mild cognitive impairment (PD-MCI). Background: MCI is a risk factor for dementia…Early caudate involvement in Parkinson’s disease may predict future cognitive decline
Objective: 1. To investigate prevalence of caudate dopaminergic dysfunction as measured by 123I-FP-CIT in a large cohort of early stage (< 2 years disease duration)…
- « Previous Page
- 1
- …
- 305
- 306
- 307
- 308
- 309
- …
- 405
- Next Page »